EF Hutton analyst Jason Kolbert initiated coverage of Invivyd (IVVD) with a Buy rating and $9 price target Invivyd is a biopharmaceutical company that develops antibody-based therapies to prevent and treat infectious diseases, the analyst tells investors in a research note. The firm says the company’s platform combines rapid antibody discovery with an understanding of viral mutations, allowing for the creation of adaptable treatments against evolving viral threats.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd pulls 2024 revenue guidance on ‘recent growth headwind’
- Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M
- Invivyd announces 12-month exploratory data from CANOPY Phase 3 trial
- Invivyd announces FDA update on Pemgarda fact sheet for SARS-CoV-2 variants
- Invivyd provides virology data, analysis of SARS-CoV-2 structural biology